It is made available under a CC-BY-NC-ND 4.0 International license .

## 1 Title

- 2 Year-round RSV Transmission in the Netherlands Following the COVID-19 Pandemic A
- 3 Prospective Nationwide Observational and Modeling Study

## 4 Authors

- 5 Yvette N. Löwensteyn (1)<sup>\*</sup>, Zhe Zheng (2)<sup>\*</sup>, Neele Rave (1), Michiel A.G.E. Bannier (3),
- 6 Marie-Noëlle Billard (1), Jean-Sebastien Casalegno (4), Virginia E. Pitzer (2), Joanne G.
- 7 Wildenbeest (1), Daniel M. Weinberger (2), Louis Bont (1), on behalf of the SPREAD study

8 group<sup>•</sup>

9

## 10 Affiliations

11 (1) Department of Pediatric Immunology and Infectious Diseases, Wilhelmina Children's

12 Hospital, P.O. Box 85090, 3508 AB Utrecht, the Netherlands

- 13 (2) Department of Epidemiology of Microbial Diseases and the Public Health Modeling Unit,
- 14 Yale School of Public Health, New Haven, CT, USA
- 15 (3) Department of Pediatric Respiratory Medicine, Maastricht University Medical Center,
- 16 Maastricht, the Netherlands
- 17 (4) Department of Microbiology, Hospices Civils de Lyon, Lyon University Medical Center,
- 18 Lyon, France
- 19

# 20 Correspondence

- 21 Louis Bont, Department of Pediatric Immunology and Infectious Diseases, Wilhelmina
- 22 Children's Hospital, P.O. Box 85090, 3508 AB Utrecht, the Netherlands. E-mail:
- 23 <u>l.bont@umcutrecht.nl</u>

It is made available under a CC-BY-NC-ND 4.0 International license .

24

## 25 \*Shared first authorship

26 ♦ SPREAD study group collaborators:

27 Marlies Vermaas - van Putten (Admiraal de Ruyter Ziekenhuis), Elly Smit-Kleinlugtenbeld 28 (Albert Schweitzer Ziekenhuis), Marieke Peetsold (Alrijne Ziekenhuis), Martijn van der Kuip, 29 Hans van Goudoever, Britt van Keulen (Amsterdam Universitair Medisch Centrum), Anouk 30 Boot, Robin Kloos (St. Antonius Ziekenhuis), Sandy van Gool (Antonius Zorggroep Sneek), 31 Yvonne Snepvangers (Beatrix Ziekenhuis), Anke Kuijpers (Bernhoven Ziekenhuis), Negassi 32 Menelik (BovenIJ Ziekenhuis), Stephanie de Crom (Bravis Ziekenhuis), Carien Miedema 33 (Catharina Ziekenhuis), Gavin ten Tusscher, Jet van Giessen (Dijklander Ziekenhuis), Ronald de Moor (Elizabeth-TweeSteden Ziekenhuis), Marianne Faber, Mijke Breukels (Elkerliek 34 Ziekenhuis), Vincent Jaddoe, Liesbeth Duijts (Erasmus Medisch Centrum), Claire Lutterman 35 36 (Flevoziekenhuis), Ilka Vink, Gerdien Tramper-Stranders (Franciscus Gasthuis & Vlietland), 37 Annemarie Oudshoorn, Astrid Ritman (Gelre Ziekenhuis), Gerdien Dubbink-Verheij (Groene 38 Hart Ziekenhuis), Jantien Bolt, Cagri Cakir (Haaglanden Medisch Centrum), Edwin Rietveld 39 (IJsselland Ziekenhuis), Jolita Bekhof (Isala), Edmond Rings, Jara de Swart (Leids 40 Universitair Medisch Centrum), Gertjan Driessen (Maastricht University Medical Center), Rienus Doedens (Martini Ziekenhuis), Lieke Nijssen, Lonneke van Onzenoort - Bokken 41 42 (Maxima Medisch Centrum), Ruud Meijneke (Meander Medisch Centrum), Machteld van Scherpenzeel, Tina Faber (Medisch Centrum Leeuwarden), Femke de Groof (Noordwest 43 Ziekenhuisgroep), Julia van de Zande, Monique op de Coul (Onze Lieve Vrouw Gasthuis), 44 Stefanie Henriet, Kim Stol (Radboud Universitair Medisch Centrum), Maaike van Rossem 45 (Rijnstate Ziekenhuis), Monique Jacobs (Slingeland Ziekenhuis), Marlies van Houten 46 (Spaarne Gasthuis), Roy Zuurbier, Frans Plötz (Tergooi Medisch Centrum), Andra de Vries 47 48 (Treant Zorggroep), Rinske van der Heide (Universitair Medisch Centrum Groningen),

medRxiv preprint doi: https://doi.org/10.1101/2022.11.10.22282132; this version posted November 11, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

49	Anneke van Boekholt (VieCuri), Gieneke Gonera - de Jong (Wilhelmina Ziekenhuis Assen),
50	Amara Nassar - Sheikh Rashid, Manouck Roelofs (Zaans Medisch Centrum), Károly Illy
51	(Ziekenhuis Rivierenland), Naomi Reijmerink (Ziekenhuis St Jansdal), Stefan van Dorth
52	(Ziekenhuis Tjongerschans), Saskia Schipper (ZorgSaam), Philippe Rosias (Zuyderland
53	Medisch Centrum), Anne Teirlinck (Rijksinstituut voor Volksgezondheid en Milieu)
54	

- 55 Word count
- 56 Abstract: 50/50
- 57 Manuscript: 1499/1500

It is made available under a CC-BY-NC-ND 4.0 International license .

# 58 ABSTRACT

- A nationwide prospective study showed year-round RSV transmission in the Netherlands after an initial 2021 summer outbreak. The pattern was unprecedented and distinct from neighboring countries. Our dynamic simulation model suggests that this transmission pattern could be associated with waning immunity because of low RSV circulation during the COVID-19 pandemic.
- 64
- 65 Keywords. Respiratory syncytial virus; transmission; epidemic timing; seasonality; COVID-
- 66 19; waning immunity; immunity debt

It is made available under a CC-BY-NC-ND 4.0 International license .

## 67 **INTRODUCTION**

Before the COVID-19 pandemic, RSV epidemics occurred annually during winter in 68 69 temperate climates (Figure 1A). During winter 2020/2021, RSV was virtually absent 70 following the implementation of COVID-19-related non-pharmaceutical interventions (NPIs) [1, 2]. After NPIs relaxed, various patterns of re-emergent RSV epidemics were observed in 71 72 different countries. Several studies suggested that school reopening is associated with 73 increased RSV activity [1, 3]. However, little attention has been paid to the impact of 74 increased RSV susceptibility in children and adults due to low RSV exposure during the 75 pandemic ("immunity debt") on the patterns of resurgence [4].

Using a combination of prospective surveillance data from the Netherlands and simulation models, this study aims to (1) describe the unusual endemic pattern of RSV between May 2021 and August 2022 and (2) illustrate the impact of waning population immunity on the timing, intensity, and persistence of the re-emergent RSV epidemic. This study provides an opportunity to advance our understanding of the drivers of re-emergent RSV epidemics.

It is made available under a CC-BY-NC-ND 4.0 International license .

### 82 **METHODS**

#### 83 Study Design

84 We initiated a prospective nationwide surveillance study (SPREAD study: surveillance of 85 pediatric respiratory admissions in Dutch hospitals) in which real-time data are collected on 86 RSV-related pediatric hospitalizations in 46 hospitals throughout the Netherlands 87 (Supplementary Table 1). In 10 hospitals with standard-of-care RSV testing, clinical patient 88 data are collected (**Supplementary Figure 1**). For this paper, we collected data from May 3, 89 2021 (week 18) until September 4, 2022 (week 35). Age-stratified data were collected from 90 October 2018 until June 2022. The study population included all children between 0-2 years 91 of age who were hospitalized with RSV-bronchiolitis in participating hospitals. 92 Collaborators of participating hospitals were requested to share data on a weekly basis. 93 Follow-ups and data verification were performed by the study team to ensure data quality. 94 Data were entered into the Castor Electronic Data Capture (EDC) system [5]. We analyzed 95 potential differences in the age distribution of patients during the following periods: pre-96 COVID-19 (2018/2019 and 2019/2020 winter season (October-April)), post-COVID-19 97 summer outbreak (May-August 2021) and post-COVID-19 endemic phase (September 2021-98 August 2022). Retrospective data were collected using diagnosis treatment combination (DBC) 99 codes (3210 - RSV-bronchiolitis; 3208 - lower respiratory tract infection; 3104 - upper 100 respiratory tract infection), and RSV-positive admissions were manually selected using 101 patient files. We used the Mann-Whitney-U test to determine statistically significant 102 differences (defined as p<0.05) between subgroups. Analyses were performed with SPSS version 26.0 (IBM Corp, Armonk, NY). 103

104

### 105 Evaluating Different Hypotheses Using Simulation Models

medRxiv preprint doi: https://doi.org/10.1101/2022.11.10.22282132; this version posted November 11, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

We modified our previously published age-stratified RSV transmission model that accounts for population dynamics, RSV seasonality, and virus importation from external sources to account for waning immunity (**Supplementary Modeling Methodology**) [6]. Our previous model assumed that individuals gain partial immunity following infection, which reduces their susceptibility to subsequent infections. By adding waning immunity, we assumed that individuals can become susceptible to infection after a long period of low virus exposure.

112 Several factors could explain differences in the timing and intensity of RSV epidemics 113 before and after the COVID-19 pandemic, including length and strength of NPIs, RSV 114 importation from external sources, increased birth rate in the Netherlands during COVID-19, 115 and waning population immunity against RSV due to absent RSV circulation. We simulated 116 RSV transmission from July 2018 to June 2025 to evaluate the various factors' impact on the 117 projected trajectories of RSV hospitalizations and qualitatively compared these to the 118 observed re-emergent RSV epidemic in the Netherlands. The four scenarios that we evaluated 119 were (1) moderate level of NPIs and low level of virus importation, no waning immunity; (2) 120 moderate level of NPIs and low level of virus importation, with waning immunity; (3) 121 moderate level of NPIs and high level of virus importation, with waning immunity; (4) strict 122 NPIs but high level of virus importation, with waning immunity (Supplementary Table 5). 123 We developed a free-to-use web-based Shiny app to allow researchers to simulate re-124 emergent RSV under the impact of various factors. We provide an interactive example at 125 https://3wxpl3-zhe-zheng.shinyapps.io/shiny/. Data and code to reproduce this study are 126 available from GitHub (https://github.com/weinbergerlab/SPREAD.git).

127

128 **RESULTS** 

## 129 **RSV-related Pediatric Hospitalizations**

medRxiv preprint doi: https://doi.org/10.1101/2022.11.10.22282132; this version posted November 11, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Starting from May 24, 2021 (week 21), a summer outbreak of RSV was observed. During the
peak week (July 19, week 29), 240 patients were admitted with RSV-bronchiolitis.
Subsequently, continuous RSV transmission was observed, with RSV-related admissions
stabilizing at approximately 50 patients weekly (Figure 1B).

134

## 135 Older Patients During and After the 2021 Summer Outbreak

We obtained age-stratified data for 988 patients admitted with RSV infection for 2018-2022 136 137 in 10 hospitals (Supplementary Table 2). The proportion of patients <6 months was higher 138 during pre-COVID-19 winter seasons. Median age during pre-COVID-19 winter seasons 139 2018/2019 and 2019/2020 was 69 days (IQR 35-176). During the summer outbreak, median 140 age increased to 161 days (IQR 56-383) (p<0.001). During the endemic phase (September 141 2021 - August 2022), median age decreased again to 137 days (IQR 54-281) but was still 142 higher than during pre-COVID winter seasons (p<0.001) (Supplementary Figure 2). As a 143 sensitivity analysis, we excluded patients from the only academic hospital (UMCU), which 144 contributed a large number of patients (21% pre-COVID-19 versus 11% during the summer 145 outbreak and 14% during the endemic phase). Differences between groups remained 146 unchanged (Supplementary Table 3).

147

### 148 Association of Waning Population Immunity with RSV Epidemic Timing

A model that assumed moderate NPIs, low virus importation, and waning population
immunity against RSV due to low RSV circulation (Scenario 2) most closely resembled the
Dutch situation: a large summer outbreak followed by continuous RSV transmission (Figure
Under this scenario, the proportion of RSV hospitalizations in children >1 year was
expected to be higher during the summer outbreak than during a typical winter season. This

It is made available under a CC-BY-NC-ND 4.0 International license .

proportion decreased over time during the following "endemic" phase. Alternative scenarios that assumed no waning RSV immunity failed to generate a summer outbreak in 2021 that was more intense than previous winter epidemics (**Supplementary Figure 4A**). A model that assumed strict NPIs, high level of virus importation, and waning immunity after a prolonged period of low viral exposure (Scenario 4) most closely resembled RSV activity in Germany and France: RSV activities returned to normal winter epidemics after a small outbreak in Spring 2021 (**Supplementary Figure 4C**).

161

It is made available under a CC-BY-NC-ND 4.0 International license .

### 162 **DISCUSSION**

163 The Netherlands exhibited a unique pattern of RSV re-emergence during the COVID-164 19 pandemic characterized by a high summer peak in 2021 followed by a prolonged period of 165 continuous transmission at mid- to high-level RSV activity. Our model simulations confirm 166 that population "immunity debt" can explain the large RSV summer outbreak and the 167 following "endemic phase" (Supplementary Figure 5) [4, 7-9]. Additionally, NPIs were 168 gradually re-implemented between mid-November 2021 and end-of-January 2022. This 169 combined with school holidays in December and mid-February may also have contributed to a 170 stagnation of RSV activity.

The year-round continuous RSV transmission pattern is distinctive not only from prepandemic winter epidemics in the Netherlands but also from neighboring countries such as Germany and France. These two countries returned to a winter epidemic in 2021 with low RSV activity during the summer of 2022. NPIs strictness and virus importation from external sources could explain these observed variations in RSV seasonality as these factors shape the level of population immunity debt [6, 9] (**Supplementary Figure 4C**). Furthermore, differences in surveillance and reporting strategies may explain the observed difference.

Our results suggest that although a shift in RSV seasonality may occur after implementation and subsequent relaxation of NPIs, RSV activity will most likely return to normal epidemic timing because herd immunity against RSV infection will return to prepandemic levels after two seasons of RSV exposure. To date, our model projection is aligned with the national RSV activity report from the National Institute for Public Health and the Environment (RIVM) [10].

Our study has several limitations. First, since not all participating hospitals used standard RSV testing, we may have underestimated RSV-related hospitalization rates. Some hospitals only used standard testing during the summer outbreak, which may have led to the

It is made available under a CC-BY-NC-ND 4.0 International license .

187 underestimation of hospitalizations after the outbreak. Second, data collection was not 188 standardized for each hospital. Although most hospitals shared prospective data, some used 189 DBC codes or virology results to collect retrospective data. Third, we received consistent data 190 from 34/46 hospitals for the entire study period. This may have led to underestimation of 191 hospitalization rates. Lastly, our model was not calibrated to the observed hospitalization data 192 in the Netherlands due to the short observational period. Instead, we simulated RSV 193 epidemics using parameters from previous RSV models in the United States based on Dutch 194 demographics. Although our simulations may not perfectly resemble the re-emergent RSV 195 epidemics in the Netherlands, the flexible parameter ranges in our web-based app provide an 196 opportunity for researchers from other countries to simulate re-emergent epidemics based on 197 their local demographic and epidemiological characteristics.

In summary, we describe a distinct pattern of ongoing RSV transmission following an out-of-season RSV outbreak in the Netherlands after relaxation of COVID-19-related NPIs. The pattern is different from neighboring countries and may be partly explained by "immunity debt", i.e. waning population immunity after a long period of low RSV exposure. Continuous monitoring of RSV seasonality using hospital-based data is essential to anticipate future RSV epidemics.

It is made available under a CC-BY-NC-ND 4.0 International license .

#### 204 **NOTES**

### 205 Acknowledgments

206 The authors thank the children and their families who participated in the study; Eline Bel, 207 Katja Steenhuis, Marit de Bruijne, Kiora Russel, Nathalie Oldenburger, Kayleigh 208 Vievermanns, Kim Bodaar, and Arda Yilmaz for their assistance in data collection; and all 209 nurses, nurse practitioners, supporting staff, doctors and pediatricians for their substantial and 210 ongoing effort for this study. Lastly, the authors thank the Dutch Working Group on Clinical 211 Virology (NWKV) from the Dutch Society for Clinical Microbiology (NVMM) and all 212 participating laboratories for providing the virological data from the weekly laboratory 213 virological report.

214

### 215 Disclaimer

The funder has no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication.

219

### 220 Financial support

This work was supported by ZonMw and the National Institute of Allergy and Infectious
Diseases (MIDAS Program) of the U.S. National Institutes of Health under award number
R01AI137093. The content is solely the responsibility of the authors and does not necessarily
represent the official views of the National Institutes of Health.

225

## 226 **Potential conflicts of interest**

Louis Bont has regular interaction with pharmaceutical and other industrial partners. He hasnot received personal fees or other personal benefits. University Medical Centre Utrecht

It is made available under a CC-BY-NC-ND 4.0 International license .

229 (UMCU) has received major funding ( $\geq \in 100,000$  per industrial partner) for investigator-230 initiated studies from AbbVie, MedImmune, Janssen, the Bill and Melinda Gates Foundation, 231 Nutricia (Danone) and MeMed Diagnostics. UMCU has received major cash or in kind 232 funding as part of the public private partnership IMI-funded RESCEU project from GSK, 233 Novavax, Janssen, AstraZeneca, Pfizer and Sanofi. University Medical Centre Utrecht has 234 received major funding by Julius Clinical for participating in the INFORM study sponsored 235 by MedImmune. UMCU has received minor funding for participation in trials by Regeneron 236 and Janssen from 2015-2017 (total annual estimate less than €20,000). UMCU received minor 237 funding for consultation and invited lectures by AbbVie, MedImmune, Ablynx, Bavaria 238 Nordic, MabXience, Novavax, Pfizer, Janssen (total annual estimate less than €20,000). Louis 239 Bont is the founding chairman of the ReSViNET Foundation. Virginia Pitzer has received 240 reimbursement from Merck and Pfizer for travel expenses to Scientific Input Engagements on 241 respiratory syncytial virus. Daniel Weinberger has received consulting fees from Pfizer, 242 Merck, GSK, Affinivax, and Matrivax for work unrelated to this manuscript and is the 243 principal investigator on research grants from Pfizer and Merck on work unrelated to this 244 manuscript. Zhe Zheng is expected to receive consulting fees from Pfizer for work unrelated 245 to this manuscript. No other conflicts of interest exist. All authors have submitted the ICMJE 246 Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider 247 relevant to the content of the manuscript have been disclosed.

It is made available under a CC-BY-NC-ND 4.0 International license .

## 248 **REFERENCES**

- Billard MN, van de Ven PM, Baraldi B, Kragten-Tabatabaie L, Bont LJ, Wildenbeest
   JG. International changes in respiratory syncytial virus (RSV) epidemiology during
   the COVID-19 pandemic: Association with school closures. Influenza and other
- respiratory viruses **2022**; 16(5): 926-36.
- 253 2. van Summeren J, Meijer A, Aspelund G, et al. Low levels of respiratory syncytial
  254 virus activity in Europe during the 2020/21 season: what can we expect in the coming
  255 summer and autumn/winter? Eurosurveillance 2021; 26(29).
- Li Y, Wang X, Cong B, Deng S, Feikin DR, Nair H. Understanding the Potential
  Drivers for Respiratory Syncytial Virus Rebound During the Coronavirus Disease
  2019 Pandemic. The Journal of infectious diseases 2022; 225(6): 957-64.
- Billard MN, Bont LJ. Quantifying the RSV immunity debt following COVID-19: a
  public health matter. Lancet Infect Dis 2022.
- 261 5. Castor Electronic Data Capture system. 2021 Available at:
   262 https://www.castoredc.com/electronic-data-capture-system/. Accessed February 9.
- 263
   264
   264
   265
   266
   266
   267
   268
   268
   269
   269
   260
   260
   260
   261
   261
   262
   263
   264
   264
   265
   266
   266
   267
   268
   269
   269
   269
   260
   260
   260
   261
   261
   262
   263
   264
   264
   264
   264
   265
   266
   266
   267
   268
   269
   269
   269
   260
   260
   260
   261
   261
   261
   262
   263
   264
   264
   264
   264
   264
   264
   264
   264
   264
   264
   264
   264
   264
   264
   264
   264
   264
   264
   264
   264
   264
   264
   264
   264
   264
   264
   264
   264
   264
   264
   264
   264
   264
   264
   264
   264
   264
   264
   264
   264
   264
   264
   264
   264
   264
   264
   264
   264
   264
   264
   264
   264
   264
   264
   264
   264
   264
   264
   264
   264
   264
   264
   264
   264
   264
- 19 Pandemic in the US. JAMA Netw Open 2021; 4(12): e2141779.
  7. Reicherz F, Xu RY, Abu-Raya B, et al. Waning immunity against respiratory syncytial
- virus during the COVID-19 pandemic. The Journal of infectious diseases 2022.
  Bardsley M, Morbey RA, Hughes HE, et al. Epidemiology of respiratory syncytial
- blackstey N, Workey N, Hughes HL, et al. Epidemology of respiratory syncytal
   virus in children younger than 5 years in England during the COVID-19 pandemic,
   measured by laboratory, clinical, and syndromic surveillance: a retrospective
   observational study. Lancet Infect Dis 2022.
- 272 9. Koltai M, Krauer F, Hodgson D, et al. Determinants of RSV epidemiology following
  273 suppression through pandemic contact restrictions. Epidemics 2022; 40: 100614.
- RIVM. State of affairs RS (respiratory syncytial) virus. RS virus no longer increased
   in the Netherlands. 2022 Available at: <u>https://www.rivm.nl/rs-virus/stand-van-zaken-</u>
   <u>rs-virus</u>.
- ECDC. Data on country response measures to COVID-19. 2022 Available at:
   <a href="https://www.ecdc.europa.eu/en/publications-data/download-data-response-measures-covid-19">https://www.ecdc.europa.eu/en/publications-data/download-data-response-measures-covid-19</a>.


280

It is made available under a CC-BY-NC-ND 4.0 International license .

## 281 TABLES AND FIGURES

282

- **Figure 1**. Respiratory Syncytial Virus Activity in the Netherlands.
- A. Respiratory Syncytial Virus Activity in the Netherlands Before the COVID-19 Pandemic.



285

286 Source: Weekly virological surveillance of Dutch Working Group for Clinical Virology of the




288

289

B. Weekly Number of Children Younger Than 2 Years of Age Admitted with RSV Infection

in The Netherlands Between May 2021 - August 2022.

It is made available under a CC-BY-NC-ND 4.0 International license .




Grey shaded areas = period of school closure. 294



It is made available under a CC-BY-NC-ND 4.0 International license .

- **Figure 2.** Simulated number of monthly respiratory syncytial virus (RSV) hospitalizations in
- children <2 years of age in the Netherlands, 2018–2025, for the model including waning of
- 297 immunity.

298



300 The year 2018-2019 corresponds to the RSV hospitalizations before the COVID-19 pandemic. 301 We assumed that COVID-19-related public health measures started in April 2020 and 302 gradually relaxed since March 2021 over a 3-month period [11]. The projected RSV 303 hospitalizations after the interruption of COVID-19-related measures over time are plotted for 304 2021 to 2025. The green line corresponds to the total RSV hospitalizations in children under 2 305 years of age. The orange line corresponds to the RSV hospitalizations in infants under 6 306 months of age. The purple line corresponds to the RSV hospitalizations in children 1 year of 307 age. The shaded area corresponds to the period of the SPREAD study, May 2021 - August 308 2022.